Predictive value of a nomogram model for treatment response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer

Table 1 Comparison of clinical characteristics between good response and poor response groups following neoadjuvant chemoradiotherapy in locally advanced rectal cancer, mean ± SD/n (%)

Variable	Good response group (n = 36)	Poor response group (n = 142)	χ²/t value	P value
Age (years)	55.1 ± 5.4	56.0 ± 6.3	0.787	0.433
Gender (male/female)	22/14	92/50	0.169	0.681
BMI (kg/m²)	23.4 ± 1.2	23.5 ± 1.5	0.371	0.711
Hypertension	12 (33.33)	43 (30.28)	0.125	0.723
Coronary artery disease	9 (25.00)	28 (19.72)	0.487	0.486
CEA level (ng/mL)	5.4 ± 1.2	5.6 ± 1.5	0.742	0.459
Smoking	17 (47.22)	64 (45.07)	0.054	0.817
Diabetes	9 (25.00)	34 (23.94)	0.017	0.895
Family history of malignancy	16 (44.44)	54 (38.03)	0.496	0.482
High-salt, high-fat diet	15 (41.67)	58 (40.85)	0.008	0.929
Distance from the anal verge (cm)	5.1 ± 1.2	5.3 ± 1.5	0.742	0.459
Pathological type (adenocarcinoma/mucinous carcinoma)	17/19	90/52	3.127	0.077
Lymph node metastasis	12 (33.33)	78 (54.93)	5.358	0.021
Differentiation (moderate-high/low-poor)	22/14	49/93	8.477	0.004
TNM/T stage (stage 3/stage 4)	23/13	39/103	16.79	< 0.001
Maximum tumor diameter (cm)	5.3 ± 1.1	6.7 ± 1.3	5.941	< 0.001

BMI: Body mass index; CEA: Carcinoembryonic antigen; TNM: Tumor node metastasis.